Apolipoprotein E
Alternative Names: Apo A4; Apo E; Apolipoprotein A1Latest Information Update: 24 Oct 2021
At a glance
- Originator Mitsubishi Chemical; Savient Pharmaceuticals
- Class Antihyperlipidaemics
- Mechanism of Action Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia; Kaposi's sarcoma
Most Recent Events
- 02 Jul 2004 Nuvelo is not continuing development of Apolipoprotein E
- 20 May 1999 Preclinical development for Kaposi's sarcoma in USA (Unknown route)
- 08 Jan 1998 Discontinued-Preclinical for Hyperlipidaemia in USA (Unknown route)